CR20160289A - Compuestos de inhibidor de autotaxina - Google Patents
Compuestos de inhibidor de autotaxinaInfo
- Publication number
- CR20160289A CR20160289A CR20160289A CR20160289A CR20160289A CR 20160289 A CR20160289 A CR 20160289A CR 20160289 A CR20160289 A CR 20160289A CR 20160289 A CR20160289 A CR 20160289A CR 20160289 A CR20160289 A CR 20160289A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- inhibitor compounds
- autotaxin inhibitor
- autotaxin
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940122849 Autotaxin inhibitor Drugs 0.000 title 1
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 abstract 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907965P | 2013-11-22 | 2013-11-22 | |
| US201462038121P | 2014-08-15 | 2014-08-15 | |
| PCT/US2014/066706 WO2015077503A1 (en) | 2013-11-22 | 2014-11-20 | Autotaxin inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160289A true CR20160289A (es) | 2016-09-27 |
Family
ID=53180152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160289A CR20160289A (es) | 2013-11-22 | 2014-11-20 | Compuestos de inhibidor de autotaxina |
| CR20190394A CR20190394A (es) | 2013-11-22 | 2014-11-20 | Compuestos de inhibidores de autotaxina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190394A CR20190394A (es) | 2013-11-22 | 2014-11-20 | Compuestos de inhibidores de autotaxina |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US9334261B2 (enExample) |
| EP (2) | EP3878848A1 (enExample) |
| JP (1) | JP6501367B2 (enExample) |
| KR (2) | KR102515248B1 (enExample) |
| CN (2) | CN105793253B (enExample) |
| AU (2) | AU2014352888B2 (enExample) |
| BR (1) | BR112016010220B1 (enExample) |
| CA (1) | CA2930737C (enExample) |
| CL (1) | CL2016001231A1 (enExample) |
| CR (2) | CR20160289A (enExample) |
| CY (1) | CY1124407T1 (enExample) |
| DK (1) | DK3071561T3 (enExample) |
| EA (1) | EA030068B1 (enExample) |
| ES (1) | ES2875899T3 (enExample) |
| HR (1) | HRP20210957T1 (enExample) |
| HU (1) | HUE055213T2 (enExample) |
| IL (2) | IL245383B (enExample) |
| LT (1) | LT3071561T (enExample) |
| MX (2) | MX375706B (enExample) |
| MY (1) | MY182095A (enExample) |
| NI (1) | NI201600071A (enExample) |
| NZ (1) | NZ720478A (enExample) |
| PE (1) | PE20160654A1 (enExample) |
| PH (1) | PH12016500862B1 (enExample) |
| PL (1) | PL3071561T3 (enExample) |
| PT (1) | PT3071561T (enExample) |
| RS (1) | RS62027B1 (enExample) |
| SI (1) | SI3071561T1 (enExample) |
| SM (1) | SMT202100531T1 (enExample) |
| WO (1) | WO2015077503A1 (enExample) |
| ZA (2) | ZA201603083B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN09346A (enExample) | 2012-06-13 | 2015-07-17 | Hoffmann La Roche | |
| MA37940B1 (fr) | 2012-09-25 | 2018-09-28 | Hoffmann La Roche | Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses. |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| JP2016531874A (ja) | 2013-09-26 | 2016-10-13 | ファーマケア，インク． | オートタキシン阻害剤化合物 |
| EA201690880A1 (ru) | 2013-11-22 | 2016-12-30 | Фармакеа, Инк. | Тетрациклические ингибиторы аутотаксина |
| CA2930737C (en) | 2013-11-22 | 2023-02-21 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| UA118201C2 (uk) | 2013-11-26 | 2018-12-10 | Ф. Хоффманн-Ля Рош Аг | НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ |
| EP3590939A1 (en) | 2014-03-26 | 2020-01-08 | F. Hoffmann-La Roche AG | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| SG10201911204WA (en) | 2015-05-27 | 2020-02-27 | Pharmakea Inc | Autotaxin inhibitors and uses thereof |
| PE20180479A1 (es) | 2015-09-04 | 2018-03-07 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
| CA2984585A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| CR20180057A (es) | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. |
| MX2018002217A (es) | 2015-09-24 | 2018-03-23 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de autotaxina (atx). |
| PE20180451A1 (es) | 2015-09-24 | 2018-03-05 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| US11000142B2 (en) | 2016-12-06 | 2021-05-11 | John Joseph Girard | Flexible floor mat incorporating LED lighting |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| WO2019046338A1 (en) | 2017-08-28 | 2019-03-07 | Angiex, Inc. | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE |
| AU2020228060A1 (en) | 2019-02-27 | 2021-09-16 | Angiex, Inc. | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same |
| CN120112527A (zh) * | 2022-05-03 | 2025-06-06 | 迪方知识产权收购有限责任公司 | 自分泌运动因子抑制剂cudetaxestat的多晶型形式和盐形式 |
| CN116239577A (zh) * | 2023-03-27 | 2023-06-09 | 沈阳药科大学 | 一种制备Cudetaxestat的方法 |
| CN116396205B (zh) * | 2023-04-20 | 2024-10-01 | 沈阳药科大学 | 一种n-芳基吲哚衍生物及其制备方法和应用 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210574A (en) | 1991-03-08 | 1993-05-11 | Mita Industrial Co., Ltd. | Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum |
| US5186522A (en) | 1991-09-24 | 1993-02-16 | Midland Brake, Inc. | Air dryer purge line |
| DE69316741T2 (de) | 1992-11-10 | 1998-09-10 | Caterpillar Inc | Magnetventil |
| US5407368A (en) | 1992-12-15 | 1995-04-18 | Minnesota Mining And Manufacturing Company | Electrode connector |
| US5761473A (en) | 1993-01-08 | 1998-06-02 | International Business Machines Corporation | Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking |
| US5564949A (en) | 1995-01-05 | 1996-10-15 | Thomas & Betts Corporation | Shielded compact data connector |
| JP2664048B2 (ja) | 1995-03-27 | 1997-10-15 | 科学技術庁金属材料技術研究所長 | 六フッ化二ケイ素の合成法 |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| WO2001030343A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
| US6890933B1 (en) | 2000-02-24 | 2005-05-10 | President And Fellows Of Harvard College | Kinesin inhibitors |
| ATE332903T1 (de) | 2000-10-03 | 2006-08-15 | Lilly Icos Llc | Kondensierte pyridoindolderivate |
| CA2444501C (en) | 2001-04-11 | 2009-11-17 | Idenix (Cayman) Limited | Phenylindoles for the treatment of hiv |
| IL160752A0 (en) * | 2001-09-27 | 2004-08-31 | Hoffmann La Roche | Indole derivatives as cox ii inhibitors |
| US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| DK1537078T3 (da) | 2002-08-29 | 2010-08-02 | Merck Sharp & Dohme | Indoler med anti-diabetisk aktivitet |
| US7393960B2 (en) | 2002-08-29 | 2008-07-01 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| AU2004240649A1 (en) | 2003-05-19 | 2004-12-02 | Irm, Llc | Immunosuppressant compounds and compositions |
| JP4090491B2 (ja) | 2003-12-23 | 2008-05-28 | ハー・ルンドベック・アクチエゼルスカベット | ２−（１ｈ−インドリルスルファニル）−ベンジルアミン誘導体 |
| JP4714143B2 (ja) | 2004-05-19 | 2011-06-29 | 住友電気工業株式会社 | Ｉｉｉ族窒化物半導体結晶の製造方法 |
| KR101141650B1 (ko) | 2004-09-30 | 2012-05-17 | 엘지전자 주식회사 | 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말 |
| WO2006041961A1 (en) | 2004-10-05 | 2006-04-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES | Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
| WO2006050236A2 (en) | 2004-11-01 | 2006-05-11 | Nuada, Llc | Compounds and methods of use thereof |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| US20060270634A1 (en) | 2005-05-06 | 2006-11-30 | Miller Duane D | Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors |
| AR054394A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
| WO2007041600A2 (en) | 2005-10-03 | 2007-04-12 | Luminescent Technologies, Inc. | Mask-pattern determination using topology types |
| JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| US8722649B2 (en) | 2007-06-15 | 2014-05-13 | University Of Utah Research Foundation | Alpha-chloro and alpha-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof |
| DE102007047738A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
| DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| DE102007047735A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Thiazolderivate |
| US8268891B1 (en) | 2007-11-13 | 2012-09-18 | University Of Memphis Research Foundation | Autotaxin inhibitors |
| US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
| WO2009151644A2 (en) | 2008-06-13 | 2009-12-17 | Yale University | Small molecule inhibitors of autotaxin methods of use |
| US8022239B2 (en) | 2008-10-03 | 2011-09-20 | The University Of Memphis Research Foundation | Mechanism-based inactivators of autotaxin |
| DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
| US8530650B2 (en) | 2008-12-01 | 2013-09-10 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer |
| US8841324B2 (en) * | 2009-04-02 | 2014-09-23 | Merck Patent Gmbh | Heterocyclic compounds as autotaxin inhibitors |
| AU2010234087B2 (en) | 2009-04-02 | 2016-05-12 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
| JP5779172B2 (ja) | 2009-04-02 | 2015-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オートタキシン阻害剤 |
| US8445200B2 (en) | 2009-04-15 | 2013-05-21 | The Regents Of The University Of California | Genotoxicity as a biomarker for inflammation |
| EP2429511B1 (en) | 2009-05-11 | 2019-02-20 | Berg LLC | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| WO2010133970A1 (en) | 2009-05-20 | 2010-11-25 | Eth Zurich | Targeting micrornas for metabolic disorders |
| WO2011002918A1 (en) | 2009-06-30 | 2011-01-06 | The University Of Memphis Research Foundation | Novel diverse lead compound autotaxin inhibitors |
| DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
| DE102009049211A1 (de) | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
| WO2011049433A1 (en) | 2009-10-23 | 2011-04-28 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Diagnosis and treatment of pruritis |
| WO2011053597A1 (en) | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| JP5827677B2 (ja) * | 2010-03-26 | 2015-12-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オートタキシン阻害剤としてのベンゾナフチリジンアミン |
| JP5767314B2 (ja) | 2010-04-16 | 2015-08-19 | ソーク インスティチュート フォー バイオロジカル スタディーズ | Ｆｇｆを用いて代謝障害を処置するための方法 |
| US9000025B2 (en) | 2010-08-20 | 2015-04-07 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| US8673882B2 (en) | 2011-01-20 | 2014-03-18 | University Of Tennessee Research Foundation | Inhibitors of autotaxin |
| US8815843B2 (en) | 2011-02-18 | 2014-08-26 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| US20140086839A1 (en) | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| GB2494154B (en) | 2011-08-31 | 2017-11-29 | Metaswitch Networks Ltd | Conditional telecommunications |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
| CA2853231C (en) | 2011-10-28 | 2020-08-04 | Inhibitaxin Limited | Pyridazine derivatives with autotaxin activity for use in therapy |
| JP2013129632A (ja) | 2011-12-22 | 2013-07-04 | Ono Pharmaceut Co Ltd | Ｅｎｐｐ２阻害化合物 |
| US20130270634A1 (en) | 2012-04-12 | 2013-10-17 | Richtek Technology Corporation | High voltage device and manufacturing method thereof |
| IN2014DN09346A (enExample) | 2012-06-13 | 2015-07-17 | Hoffmann La Roche | |
| WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| MA37940B1 (fr) | 2012-09-25 | 2018-09-28 | Hoffmann La Roche | Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses. |
| US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
| HK1212348A1 (en) | 2012-12-19 | 2016-06-10 | Novartis Ag | Autotaxin inhibitors |
| TWI499591B (zh) | 2013-01-11 | 2015-09-11 | Lilly Co Eli | 雙環嘧啶化合物 |
| US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| JP2016531874A (ja) * | 2013-09-26 | 2016-10-13 | ファーマケア，インク． | オートタキシン阻害剤化合物 |
| DK3066080T5 (en) | 2013-11-05 | 2018-09-17 | Bayer Cropscience Ag | SUBSTITUTED BENZAMIDES FOR TREATMENT OF ARTHROPODS |
| EA201690880A1 (ru) | 2013-11-22 | 2016-12-30 | Фармакеа, Инк. | Тетрациклические ингибиторы аутотаксина |
| CL2016001118A1 (es) | 2013-11-22 | 2016-12-02 | Basf Se | Compuestos heterocíclicos de n-acilimino |
| CA2930737C (en) | 2013-11-22 | 2023-02-21 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| PL3071560T3 (pl) | 2013-11-22 | 2018-07-31 | Basf Se | N-acyloiminowe związki heterocykliczne |
| US9051320B1 (en) * | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| SG10201911204WA (en) | 2015-05-27 | 2020-02-27 | Pharmakea Inc | Autotaxin inhibitors and uses thereof |
-
2014
- 2014-11-20 CA CA2930737A patent/CA2930737C/en active Active
- 2014-11-20 EP EP21156420.8A patent/EP3878848A1/en active Pending
- 2014-11-20 AU AU2014352888A patent/AU2014352888B2/en active Active
- 2014-11-20 DK DK14864293.7T patent/DK3071561T3/da active
- 2014-11-20 PE PE2016000669A patent/PE20160654A1/es unknown
- 2014-11-20 ES ES14864293T patent/ES2875899T3/es active Active
- 2014-11-20 KR KR1020227005531A patent/KR102515248B1/ko active Active
- 2014-11-20 KR KR1020167014496A patent/KR102367876B1/ko active Active
- 2014-11-20 SM SM20210531T patent/SMT202100531T1/it unknown
- 2014-11-20 PT PT148642937T patent/PT3071561T/pt unknown
- 2014-11-20 MX MX2016006623A patent/MX375706B/es active IP Right Grant
- 2014-11-20 CR CR20160289A patent/CR20160289A/es unknown
- 2014-11-20 WO PCT/US2014/066706 patent/WO2015077503A1/en not_active Ceased
- 2014-11-20 EA EA201690881A patent/EA030068B1/ru unknown
- 2014-11-20 LT LTEP14864293.7T patent/LT3071561T/lt unknown
- 2014-11-20 HU HUE14864293A patent/HUE055213T2/hu unknown
- 2014-11-20 SI SI201431843T patent/SI3071561T1/sl unknown
- 2014-11-20 CN CN201480063881.XA patent/CN105793253B/zh active Active
- 2014-11-20 NZ NZ720478A patent/NZ720478A/en unknown
- 2014-11-20 BR BR112016010220-7A patent/BR112016010220B1/pt active IP Right Grant
- 2014-11-20 EP EP14864293.7A patent/EP3071561B1/en active Active
- 2014-11-20 CR CR20190394A patent/CR20190394A/es unknown
- 2014-11-20 HR HRP20210957TT patent/HRP20210957T1/hr unknown
- 2014-11-20 MY MYPI2016000959A patent/MY182095A/en unknown
- 2014-11-20 RS RS20210786A patent/RS62027B1/sr unknown
- 2014-11-20 CN CN201910686732.3A patent/CN110372671B/zh active Active
- 2014-11-20 JP JP2016533532A patent/JP6501367B2/ja active Active
- 2014-11-20 PL PL14864293T patent/PL3071561T3/pl unknown
-
2015
- 2015-10-29 US US14/926,877 patent/US9334261B2/en active Active
-
2016
- 2016-03-03 US US15/060,398 patent/US9468628B2/en active Active
- 2016-05-02 IL IL24538316A patent/IL245383B/en active IP Right Grant
- 2016-05-09 ZA ZA2016/03083A patent/ZA201603083B/en unknown
- 2016-05-10 PH PH12016500862A patent/PH12016500862B1/en unknown
- 2016-05-20 NI NI201600071A patent/NI201600071A/es unknown
- 2016-05-20 MX MX2020009780A patent/MX2020009780A/es unknown
- 2016-05-20 CL CL2016001231A patent/CL2016001231A1/es unknown
- 2016-09-09 US US15/261,659 patent/US9999615B2/en active Active
-
2018
- 2018-05-03 US US15/970,337 patent/US10688081B2/en active Active
-
2019
- 2019-08-09 AU AU2019213425A patent/AU2019213425B2/en active Active
- 2019-10-24 IL IL270168A patent/IL270168B/en unknown
-
2020
- 2020-05-14 US US16/874,073 patent/US11344533B2/en active Active
- 2020-08-05 ZA ZA2020/05029A patent/ZA202005029B/en unknown
-
2021
- 2021-06-23 CY CY20211100562T patent/CY1124407T1/el unknown
-
2022
- 2022-05-06 US US17/662,403 patent/US11779568B2/en active Active
-
2023
- 2023-10-04 US US18/481,141 patent/US12268668B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX374452B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| DOP2017000048A (es) | Compuestos aminopirimidinilo como inhibidores de jak. | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| MX2016004340A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| SV2015005066A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
| BR112016023815A2 (pt) | composições tópicas para o alívio da dor, produção e uso | |
| MX2016016583A (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| ECSP14030779A (es) | Inhibidores del nampt | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. | |
| BR112015016391A2 (pt) | carboxamidas i baseadas em pirazolil como inibidoras do canal crac | |
| BR112015016394A2 (pt) | carboxamidas ii baseadas em pirazolil como inibidoras do canal crac |